A randomized, double blind, placebo-controlled, parallel-group study to evaluate the effect of SAR236553/REGN727 on the occurren - Bronson Healthcare

Elevated Cholesterol and Heart Disease

A randomized, double blind, placebo-controlled, parallel-group study to evaluate the effect of SAR236553/REGN727 on the occurrence of cardiovascular events in patients who have recently experienced an acute coronary syndrome (Odyssey Outcomes).

Objective

The purpose of this study is to see if patients who have had a heart attack and who have high cholesterol that does not respond well enough to high doses of standard therapy with statins do better when treated with the investigational drug. The drug is a monoclonal antibody that is taken as a shot under the skin every two weeks.

ClinicalTrials.Gov Number
NCT01663402
Principal Investigator(s)
Thomas Blok, MD
Sponsor(s)
Sanofi in collaboration with Regeneron Pharmaceuticals
Contact
Gail Massey, RN, BS at 269-341-8774
or masseyg@bronsonhg.com
How to Participate
Subjects will be randomly assigned to either the investigational drug or placebo and will be followed for up to 6 years. Up to 18,000 patients will enter the study at multiple sites around the world.
More information can be found here.

Location

  • Bronson Advanced Cardiac Healthcare - Kalamazoo
    601 John St.
    Suite 100
    Kalamazoo, MI 49007
    Main: 269-373-1222
    Alternate: 800-483-8333
    Fax: 269-373-6270